Rosen Law Firm Investigates Disc Medicine, Inc. Securities
Rosen Law Firm has initiated an investigation into potential securities claims concerning Disc Medicine, Inc. The inquiry focuses on allegations that the company may have issued misleading information to investors.
Rosen Law Firm, a global investor rights law firm, is continuing its investigation into potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON). The investigation centers on allegations that Disc Medicine may have issued materially misleading business information to the investing public.
The inquiry stems from a Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) on February 13, 2026, regarding Disc Medicine's bitopertin program. The FDA stated that Disc Medicine's new drug application could not be approved due to uncertainties requiring additional evidence.
Following this news, Disc Medicine's stock price declined by 22% on February 13, 2026. Rosen Law Firm is preparing a class action lawsuit to seek recovery for investor losses.
Shareholders who purchased Disc Medicine securities and may be entitled to compensation are encouraged to contact Rosen Law Firm. The firm emphasizes the importance of selecting experienced counsel for such matters. Information on joining the prospective class action is available through the firm's website.